We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current DNLI market cap is 2.37B. The company's latest EPS is USD -1.0436 and P/E is -16.11.
| Quarter End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 42.14M | 52.48M | 3.56M | 10.28M | 35.14M |
| Operating Income | -66.5M | -61.42M | -107.49M | -105.34M | -120.82M |
| Net Income | -65.22M | -58.79M | -103.3M | -98.68M | -109.78M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 26.68M | 335.66M | 48.66M | 108.46M | 330.53M |
| Operating Income | -213.18M | 62.72M | -295.75M | -340.74M | -196.7M |
| Net Income | -197.61M | 71.14M | -290.58M | -325.99M | -145.22M |
| Quarter End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.32B | 1.29B | 1.23B | 1.46B | 1.41B |
| Total Liabilities | 402.93M | 408.01M | 416.3M | 417.81M | 442.64M |
| Total Equity | 917.93M | 884.45M | 811.3M | 1.04B | 966.71M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 553.23M | 1.6B | 1.4B | 1.46B | 1.15B |
| Total Liabilities | 158.34M | 453.75M | 441.87M | 417.81M | 122.96M |
| Total Equity | 394.89M | 1.15B | 962.29M | 1.04B | 1.03B |
| Quarter End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -72.11M | -115.01M | -172.05M | -244.72M | -58.8M |
| Investing | -117.88M | -29.25M | -13.83M | -141.39M | -92.72M |
| Financing | 1.46M | 5.87M | 11.02M | 310.67M | 1.6M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -151.58M | 416.15M | -211.39M | -244.72M | -357.99M |
| Investing | 147.71M | -623.21M | -21.63M | -141.39M | 249.31M |
| Financing | 6.19M | 634.75M | 19.35M | 310.67M | 17.82M |
| Market Cap | 2.37B |
| Price to Earnings Ratio | -16.11 |
| Price to Sales Ratio | 7.08 |
| Price to Cash Ratio | 18.4 |
| Price to Book Ratio | 2.27 |
| Dividend Yield | - |
| Shares Outstanding | 139.16M |
| Average Volume (1 week) | 1.1M |
| Average Volume (1 Month) | 1.16M |
| 52 Week Change | -33.52% |
| 52 Week High | 33.31 |
| 52 Week Low | 14.56 |
| Spread (Intraday) | 1.06 (6.24%) |
| Company Name | Denali Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.denalitherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
